Race Oncology Ltd (ASX:RAC)'s Phillip Lynch speaks with Proactive during the ASX Small and Mid-Cap Conference. They're a precision oncology company with a cancer drug called Zantrene®. It's a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers.
Race Oncology with Proactive at the ASX Small and Mid-Cap Conference
